Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORNINGSKY: Bemnifosbuvir in Mild or Moderate COVID-19
NCT04889040Phase 3Terminated
- Sponsor
- Roche
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19), sponsored by Roche. Started Apr 2021; status: terminated.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04889040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04889040.